Venture Capital Investors

Ampersand Capital Partners

VC firm Ampersand Capital Partners provides capital to high-potential technology companies.

Venture Investor Overview

Venture Investor
Ampersand Capital Partners
Status
InActive
Investor Type
Venture Capital
Activity Level
4 transactions
Funds Raised
At least $690 million
Industry Focus
Biopharmaceutical
Medical Devices & Instruments

Contact Information

Contact
David Anderson
Title
General Partner
Mailing Address
55 William St. 240
Wellesley, MA 02481
USA
Phone
(781) 239-0700
Website
www.ampersandcapital.com
Email Address
[email protected]

Background Information

Overview
At Our Core, We Are A Rigorous Blend Of Science, Technology And Operations. Ampersand was founded in the late 1980s and began investing in healthcare in the early 1990s. Today, Ampersand is focused exclusively on growth equity investments in lower middle market healthcare companies. We are typically the first institutional investor in founder-owned businesses, where we work with the entrepreneur to help take the company to the next level.
Profile
Ampersand Capital Partners LinkedIn Company Profile
Social Media
Ampersand Capital Partners Company Twitter Account
Company News
Ampersand Capital Partners News
Facebook
Ampersand Capital Partners on Facebook
YouTube
Ampersand Capital Partners on YouTube
Last Transaction
6/22/2023

Transaction History

Our records indicate that Ampersand Capital Partners invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Vernal Biosciences
6/22/2023
$20,000,000
NanoImaging Services
6/12/2023
Unknown
Vernal Biosciences
6/3/2022
$21,000,000
Arranta Bio
10/31/2019
$82,000,000

 

Investor Contacts

Title
Name
Email & Social
General Partner
David Anderson
  David Anderson LinkedIn Profile  David Anderson Twitter Account  David Anderson News  David Anderson on Facebook
Partner
Stuart Auerbach
  Stuart Auerbach LinkedIn Profile  Stuart Auerbach Twitter Account  Stuart Auerbach News  Stuart Auerbach on Facebook
Partner
Mark Bamforth
  Mark Bamforth LinkedIn Profile  Mark Bamforth Twitter Account  Mark Bamforth News  Mark Bamforth on Facebook
Partner
Jared Bartok
  Jared Bartok LinkedIn Profile  Jared Bartok Twitter Account  Jared Bartok News  Jared Bartok on Facebook
Managing Partner
Richard Charpie
  Richard Charpie LinkedIn Profile  Richard Charpie Twitter Account  Richard Charpie News  Richard Charpie on Facebook
Partner
Michael Evans
  Michael Evans LinkedIn Profile  Michael Evans Twitter Account  Michael Evans News  Michael Evans on Facebook
Managing Partner
Herbert Hooper
  Herbert Hooper LinkedIn Profile  Herbert Hooper Twitter Account  Herbert Hooper News  Herbert Hooper on Facebook
Partner
Paul Johnson
  Paul Johnson LinkedIn Profile  Paul Johnson Twitter Account  Paul Johnson News  Paul Johnson on Facebook
Partner
Eric Lev
  Eric Lev LinkedIn Profile  Eric Lev Twitter Account  Eric Lev News  Eric Lev on Facebook
Partner
Laurence McCarthy
  Laurence McCarthy LinkedIn Profile  Laurence McCarthy Twitter Account  Laurence McCarthy News  Laurence McCarthy on Facebook
Partner
Dana Niles
  Dana Niles LinkedIn Profile  Dana Niles Twitter Account  Dana Niles News  Dana Niles on Facebook
General Partner
David Parker
  David Parker LinkedIn Profile  David Parker Twitter Account  David Parker News  David Parker on Facebook
Partner
David Patteson
  David Patteson LinkedIn Profile  David Patteson Twitter Account  David Patteson News  David Patteson on Facebook
Principal
Marina Pellón-Consunji
  Marina Pellón-Consunji LinkedIn Profile  Marina Pellón-Consunji Twitter Account  Marina Pellón-Consunji News  Marina Pellón-Consunji on Facebook
Partner
Dean Schauer
  Dean Schauer LinkedIn Profile  Dean Schauer Twitter Account  Dean Schauer News  Dean Schauer on Facebook
Partner
Geoffrey Teillon
  Geoffrey Teillon LinkedIn Profile  Geoffrey Teillon Twitter Account  Geoffrey Teillon News  Geoffrey Teillon on Facebook
Partner
Trevor Wahlbrink
  Trevor Wahlbrink LinkedIn Profile  Trevor Wahlbrink Twitter Account  Trevor Wahlbrink News  Trevor Wahlbrink on Facebook
Partner
Patrick Walsh
  Patrick Walsh LinkedIn Profile  Patrick Walsh Twitter Account  Patrick Walsh News  Patrick Walsh on Facebook
Partner
Frank Witney
  Frank Witney LinkedIn Profile  Frank Witney Twitter Account  Frank Witney News  Frank Witney on Facebook
Partner
Peng Zhou
  Peng Zhou LinkedIn Profile  Peng Zhou Twitter Account  Peng Zhou News  Peng Zhou on Facebook

 

Funds

Our database includes the following fund closing(s) for Ampersand Capital Partners. If we are missing funds, please contact us.

Fund Description
Vintage Date
Fund Amount
Ampersand 2020
4/1/2020
$690,000,000

 

Portfolio Companies

Ampersand Capital Partners has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
Arranta Bio
NanoImaging Services
Vernal Biosciences

 

 

 

 

Browse more venture capital investors:

Amp Ventures | Amphora Capital

 

Share this article

 

About Our Venture Capital Investors Database

This VC firm profile is powered by VentureDeal.com, a leading supplier of venture capital funding data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.